Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Cystic fibrosis (CF) in children aged between 6 and 11 years who are homozygous for the F508del mutation in the CFTR gene
Neither positive nor negative effects in comparison with the best possible symptomatic treatment; added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-08
- Commission
- Commission awarded on 01.02.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08
Status: Commission completed
-
Dossier assessment
Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)
Status: Commission completed
-
Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed